Lilly quietly completes purchase of Padcev competitor, estimated at nearly half a billion dollars

Eli Lil­ly com­plet­ed its ac­qui­si­tion of an­ti­body-drug con­ju­gate biotech Emer­gence Ther­a­peu­tics, the In­di­anapo­lis phar­ma com­pa­ny con­firmed to End­points News Wednes­day.

The buy­out closed on Aug. 24, a Lil­ly spokesper­son told End­points in an email. Lil­ly paid an es­ti­mat­ed $470 mil­lion, with $335 mil­lion in po­ten­tial mile­stones, as cal­cu­lat­ed by End­points and mul­ti­ple an­a­lysts.

Eli Lil­ly and Emer­gence’s CEO Jack Elands de­clined to con­firm the size of the deal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

try for new issue

Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.

Read More »